BioLineRx announced a multi-center Phase 1 clinical trial sponsored by St. Jude Children’s Research Hospital, Inc. to evaluate motixafortide for the mobilization of CD34+ hematopoietic stem cells used in the development of gene therapies for patients with sickle cell disease. Investigators in the trial from St. Jude Children’s Research Hospital, Inc. and two other clinical sites have extensive SCD gene therapy clinical development experience and are recognized leaders in the field.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLRX:
- BioLineRx Q1 Success with APHEXDA® Growth
- BioLineRx reports Q1 EPS 0c vs. (1c) last year
- Options Volatility and Implied Earnings Moves Today, May 28, 2024
- BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
- Options Volatility and Implied Earnings Moves This Week, May 28 – May 30, 2024